PAHC Stock Analysis: Phibro Animal Health | NASDAQ
Drug Manufacturers - Specialty & Generic | NASDAQ, USA | Market Cap: 1.555m USD | 12M Return: 1.9% | US71742Q1067 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.07M
EPS Trend: 98.1%
Qual. Beats: 4
Rev. Trend: 97.5%
Qual. Beats: 5
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Phibro Animal Health Corporation (NASDAQ: PAHC) is a Teaneck, New Jersey-based animal health and mineral nutrition company that has operated since its 1946 incorporation, originally as Philipp Brothers Chemicals, Inc. The company operates through three business segments-Animal Health, Mineral Nutrition, and Performance Products-serving food animal producers (poultry, swine, beef and dairy cattle, aquaculture) as well as companion animals (dogs) across the United States, Latin America, Canada, Europe, the Middle East, Africa, and Asia Pacific.
Its product portfolio spans antibacterials, anticoccidials, nutritional specialties, conventionally licensed and autogenous vaccines, vaccine adjuvants, and microbial and bioproducts for animal health, nutrition, environmental, industrial, and agricultural applications. The Mineral Nutrition segment supplies trace mineral formulations (zinc, copper, manganese, iron, and related compounds) used to fortify livestock feed, while the Performance Products segment offers specialty ingredients for personal care, industrial chemical, and chemical catalyst end markets. Distribution is handled through a combination of local sales offices and third-party channels including integrated producers, commercial feed manufacturers, wholesalers, and distributors.
The animal health pharmaceuticals subsector tends to be relatively defensive, supported by structural demand from global protein consumption and recurring livestock health needs. Phibros diversified mix of pharmaceuticals, vaccines, and feed-additive minerals provides exposure to both production-animal health spending and the pet care market, which has historically grown alongside rising companion animal ownership.
- Livestock antibiotic demand drives core Animal Health revenue
- International FX exposure pressures consolidated margins
- Acquisition-driven debt load constrains capital allocation flexibility
| Net Income: 99.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA -2.42 > 1.0 |
| NWC/Revenue: 40.78% < 20% (prev 39.90%; Δ 0.88% < -1%) |
| CFO/TA 0.05 > 3% & CFO 69.0m > Net Income 99.7m |
| Net Debt (762.7m) to EBITDA (236.5m): 3.23 < 3 |
| Current Ratio: 2.96 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.0m) vs 12m ago 0.74% < -2% |
| Gross Margin: 33.76% > 18% (prev 30.85%; Δ 2.91% > 0.5%) |
| Asset Turnover: 106.1% > 50% (prev 95.25%; Δ 10.83% > 0%) |
| Interest Coverage Ratio: 3.89 > 6 (EBIT TTM 184.9m / Interest Expense TTM 47.6m) |
| A: 0.41 (Total Current Assets 935.5m - Total Current Liabilities 316.5m) / Total Assets 1.50b |
| B: 0.24 (Retained Earnings 353.0m / Total Assets 1.50b) |
| C: 0.13 (EBIT TTM 184.9m / Avg Total Assets 1.43b) |
| D: 0.35 (Book Value of Equity 385.5m / Total Liabilities 1.12b) |
| Altman-Z'' = 4.70 = AA |
| DSRI: 0.89 (Receivables 238.8m/228.0m, Revenue 1.52b/1.30b) |
| GMI: 0.91 (GM 30.85% / 33.76%) |
| AQI: 1.16 (AQ_t 0.13 / AQ_t-1 0.11) |
| SGI: 1.17 (Revenue 1.52b / 1.30b) |
| TATA: 0.02 (NI 99.7m - CFO 69.0m) / TA 1.50b) |
| Beneish M = -2.97 (Cap -4..+1) = A |
As of October 14, 2026, the stock is trading at USD 36.81 with a total of 407,385 shares traded. Over the past week, the price has changed by +0.55%, over one month by +2.42%, over three months by +11.90% and over the past year by +1.88%.
Current recommended Stop Loss: 33.80 (which is 8.2% or 2.2 ATR below the current price).
Phibro Animal Health has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold PAHC.
- StrongBuy: 0
- Buy: 1
- Hold: 2
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 44 | 19.5% |
P/E Trailing = 15.7613
P/E Forward = 13.8313
P/S = 1.0243
P/B = 3.5917
P/EG = 1.6791
Revenue TTM = 1.52b USD
EBIT TTM = 184.9m USD
EBITDA TTM = 236.5m USD
Long Term Debt = 707.8m USD (from longTermDebt, last quarter)
Short Term Debt = 35.6m USD (from shortTermDebt, last quarter)
Debt = 844.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 56.0m
Net Debt = 762.7m USD (calculated: Debt 844.7m - CCE 82.0m)
Enterprise Value = 2.32b USD (1.56b + Debt 844.7m - CCE 82.0m)
Interest Coverage Ratio = 3.89 (Ebit TTM 184.9m / Interest Expense TTM 47.6m)
EV/FCF = 234.9x (Enterprise Value 2.32b / FCF TTM 9.87m)
FCF Yield = 0.43% (FCF TTM 9.87m / Enterprise Value 2.32b)
FCF Margin = 0.65% (FCF TTM 9.87m / Revenue TTM 1.52b)
Net Margin = 6.57% (Net Income TTM 99.7m / Revenue TTM 1.52b)
Gross Margin = 33.76% ((Revenue TTM 1.52b - Cost of Revenue TTM 1.01b) / Revenue TTM)
Gross Margin QoQ = 33.88% (prev 32.77%)
Tobins Q-Ratio = 1.54 (Enterprise Value 2.32b / Total Assets 1.50b)
Interest Expense / Debt = 5.64% (Interest Expense 47.6m / Debt 844.7m)
Taxrate = 27.40% (37.6m / 137.3m)
NOPAT = 134.3m (EBIT 184.9m * (1 - 27.40%))
Current Ratio = 2.96 (Total Current Assets 935.5m / Total Current Liabilities 316.5m)
Debt / Equity = 2.19 (Debt 844.7m / totalStockholderEquity, last quarter 385.5m)
Debt / EBITDA = 3.23 (Net Debt 762.7m / EBITDA 236.5m)
Debt / FCF = 77.31 (Net Debt 762.7m / FCF TTM 9.87m)
Total Stockholder Equity = 347.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 6.97% (Net Income 99.7m / Total Assets 1.50b)
RoE = 28.67% (Net Income TTM 99.7m / Total Stockholder Equity 347.8m)
RoCE = 17.52% (EBIT 184.9m / Capital Employed (Equity 347.8m + L.T.Debt 707.8m))
RoIC = 11.73% (NOPAT 134.3m / Invested Capital 1.14b)
WACC = 7.83% (E(1.56b)/V(2.40b) * Re(9.86%) + D(844.7m)/V(2.40b) * Rd(5.64%) * (1-Tc(0.27)))
Discount Rate = 9.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.89 | Cagr: 0.52%
[DCF] Terminal Value 73.10% ; FCFF base≈22.7m ; Y1≈19.9m ; Y5≈16.0m
[DCF] Fair Price = N/A (negative equity: EV 257.6m - Net Debt 762.7m = -505.1m; debt exceeds intrinsic value)
EPS Correlation: 98.14 | EPS CAGR: 54.25% | SUE: 2.63 | # QB: 4
Revenue Correlation: 97.54 | Revenue CAGR: 21.03% | SUE: 1.83 | # QB: 5
EPS current Quarter (2026-09-30): EPS=0.76 | Chg30d=-3.38% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-12-31): EPS=0.99 | Chg30d=+8.79% | Revisions=+25% | Analysts=2
EPS current Year (2027-06-30): EPS=3.50 | Chg30d=+5.49% | Revisions=+62% | GrowthEPS=+8.7% | GrowthRev=+3.8%
EPS next Year (2028-06-30): EPS=3.84 | Chg30d=+5.66% | Revisions=+57% | GrowthEPS=+9.8% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: +64% (up=10, down=1)